Thailand Medical News - For All The Latest Breaking Medical News, Health News, Research News, COVID-19 News, Outbreak News, Dengue News, Glaucoma News, Diabetes News, Herb News, Phytochemical News, Heart And Cardiology News, Epigenetic News, Cancer News,

BREAKING NEWS
Source: Pediatric COVID-19  Jul 16, 2021  2 years, 9 months, 2 days, 5 hours, 32 minutes ago

UK Study Finds That About 4 Percent Of Children Hospitalized For COVID-19 Will Ultimately Develop Neurological Complications!

UK Study Finds That About 4 Percent Of Children Hospitalized For COVID-19 Will Ultimately Develop Neurological Complications!
Source: Pediatric COVID-19  Jul 16, 2021  2 years, 9 months, 2 days, 5 hours, 32 minutes ago
Pediatric COVID-19: A new study by researchers from various British institutions and hospitals including the University of Liverpool, Great Ormond Street Hospital for Children, Evelina Children's Hospital, Leeds Teaching Hospitals NHS Trust, University of Newcastle, Oxford Children's Hospital, Nottingham Children's Hospital, University of Glasgow, University of Newcastle and many others, have found that roughly 4% of children hospitalized for COVID-19 will ultimately develop neurological complications!

To date, the degree of neurological and psychiatric complications associated with pediatric SARS-CoV-2 infection is poorly understood. The study team aimed to analyze the range and prevalence of these complications in hospitalized children and adolescents.
 
In the study , between April 2, 2020, and Feb 1, 2021, 52 cases were identified; in England, there were 51 cases among 1334 children and adolescents hospitalized with COVID-19, giving an estimated prevalence of 3·8 (95% CI 2·9–5·0) cases per 100 pediatric patients. 22 (42%) patients were female and 30 (58%) were male; the median age was 9 years (range 1–17). 36 (69%) patients were Black or Asian, 16 (31%) were White. 27 (52%) of 52 patients were classified into the COVID-19 neurology group and 25 (48%) were classified into the PIMS-TS neurology group. In the COVID-19 neurology group, diagnoses included status epilepticus (n=7), encephalitis (n=5), Guillain-Barré syndrome (n=5), acute demyelinating syndrome (n=3), chorea (n=2), psychosis (n=2), isolated encephalopathy (n=2), and transient ischaemic attack (n=1). The PIMS-TS neurology group more often had multiple features, which included encephalopathy (n=22 [88%]), peripheral nervous system involvement (n=10 [40%]), behavioural change (n=9 [36%]), and hallucinations at presentation (n=6 [24%]). Recognised neuroimmune disorders were more common in the COVID-19 neurology group than in the PIMS-TS neurology group (13 [48%] of 27 patients vs 1 [<1%] of 25 patients, p=0·0003). Compared with the COVID-19 neurology group, more patients in the PIMS-TS neurology group were admitted to intensive care (20 [80%] of 25 patients vs six [22%] of 27 patients, p=0·0001) and received immunomodulatory treatment (22 [88%] patients vs 12 [44%] patients, p=0·045). 17 (33%) patients (10 [37%] in the COVID-19 neurology group and 7 [28%] in the PIMS-TS neurology group) were discharged with disability; one (2%) died (who had stroke, in the PIMS-TS neurology group).
 
This Pediatric COVID-19 study identified key differences between those with a primary neurological disorder versus those with PIMS-TS. (Primary neurological disorder associated with COVID-19).  Compared with patients with a primary neurological disorder, more patients with PIMS-TS needed intensive care, but outcomes were